Transaction · 0001104659-26-105509

Teyssedou Lenaic Nathanael

Teyssedou Lenaic Nathanael, PAO, reported a transaction classified as grant at Addex Therapeutics Ltd. involving 59530.000000 shares for an estimated $0.00. Reported holdings after the transaction were 602908.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code APAO
ADXNAddex Therapeutics Ltd.
Filing timeSep 04
Trade dateSep 02, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$3.65
Pre-filing
1mo ago1w ago1d ago
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

ADXN price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ADXN since 2026-09-04Filed today · pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001104659-26-105509
Stock-option (Right to Buy)
Transaction date
Sep 02, 2026
Filed Sep 04, 2026, 08:11 PM · 2d delay
Shares
59.5k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
602k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Derivative Transaction Direct Ownership
-6score
Filing-only score

-6

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

PRINCIPAL ACCOUNTING OFFICER

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unc…

  2. F2

    The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.

Original filing · 0001104659-26-105509
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ADXN